Why Is Sight Sciences Stock Down Today?
SGHT is down on the session with no new company-specific headline today. The move follows an FDA-clearance pop the day before that has now fully unwound.
- SGHT is down roughly 3.8% on the day, trading near $5.32, with no new company-specific news dated today.
- The move continues the unwind of Monday, August 4's after-hours spike, when shares jumped 18.5% on FDA clearance for the OMNI Ultra glaucoma device.
- The stock is now trading below where it was before that clearance was announced.
Sight Sciences (SGHT) is down about 1.6% today, trading near $5.32. There is no new company-specific headline dated today driving the move — this is the continuation of a reversal that started the day before.
On August 4, 2026, Sight Sciences announced FDA 510(k) clearance of its OMNI Ultra Surgical System, the next-generation version of its glaucoma treatment platform. Shares jumped 18.544% within a minute of that after-hours release, from $5.77 to $6.84, on thin volume. That pop has now fully unwound: today's price is roughly 22.2% below the after-hours peak, and about 7.8% below where the stock traded before the clearance news broke.
The clearance itself was real — OMNI Ultra is cleared for canaloplasty followed by trabeculotomy to reduce eye pressure in adult primary open-angle glaucoma patients, and the company says it is the first FDA-cleared device to perform that procedure around the full drainage channel in a single pass. But a regulatory clearance is not a sales event: Sight Sciences says OMNI Ultra's commercial launch is not planned until the fourth quarter of 2026, so there is no near-term revenue tied to today's price action either way.
Historical catalyst, for context: on August 4, 2026, SGHT jumped 18.544% after hours on FDA clearance of OMNI Ultra. That is the most recent dated company news; today's move has no new headline attached to it.
Sources
-
Sight Sciences Receives FDA 510(k) Clearance of the OMNI Ultra Surgical System
— GlobeNewswire
FDA clearance details and Q4 2026 commercial launch timeline
-
Sight Sciences Gets FDA 510(k) Clearance for OMNI Ultra | SGHT Stock News
— StockTitan
Corroborates clearance and publication timing
Never miss the next market-moving story
Seven market specialists, with experience dating back to 2006, watch global markets and U.S. stocks of every size. Start Pro to get the full live feed, clear context, measured price moves, search, watchlists, and alerts.
Start Pro — $29 for 7 days Watch SGHT live -- free